ImmuPharma (LON:IMM) Stock Price Down 10% - Should You Sell?

Key Points

• ImmuPharma's stock price fell by 10%, trading as low as GBX 10.51 ($0.14) during Monday's trading session, significantly impacting its market capitalization of £56.23 million.
• Analysts predict that ImmuPharma will report a loss of -339.00 EPS for the current year, reflecting ongoing financial challenges for the company.
• The company specializes in developing peptide-based therapeutics, with its lead program, Lupuzor™, targeting autoimmune diseases like lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price dropped 10% during trading on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares changed hands during trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Trading Down 10.0%

The firm has a market capitalization of £56.23 million, a PE ratio of -1,264.38 and a beta of 1.53. The firm's fifty day moving average price is GBX 4.28 and its 200 day moving average price is GBX 3.27.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, research analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.